UCB Promotes 'Underappreciated' Pipeline In FY Results

 
• By Lucie Ellis-Taitt
  
Pipeline
UCB will see pipeline advances in 2018 for key immunology drug and early-stage neuro programs
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business